MapLight Therapeutics, Inc.
MPLT
Get informed when a big investor buys or sells
+ FollowMarket Cap$516.45M
Close$
$0.93
92% downside
Current Fair Value
92% downsideOvervalued by 92% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $516.45 Million |
|---|---|
| Enterprise Value | $466.33 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.66 |
| Beta | 2.65 |
| Outstanding Shares | 45,276,763 |
Return
| Return on Equity | -49.89% |
|---|---|
| Return on Assets | -47.63% |
| Return on Invested Capital | -51.72% |
Valuation & Multiples
| P/E Ratio | -2.66 |
|---|---|
| PEG | -1.55 |
| Price to Sales | - |
| Price to Book Ratio | 1.45 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.23 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-1.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 18, 2026
EPS Estimate
$-1.33
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.51%▼ 48.04% |
|---|---|
| Total Invested | $105.66M▼ 78.96% |
| Investors Holding | 25▼ 56.00% |
ESG Score
No data
About MapLight Therapeutics, Inc.
109 employees
CEO: Christopher A. Kroeger MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /...